Final Formulation: Managing Aggregates in Your Monoclonal Antibody (mAb) Process

Christoph Korpus, Liquid Formulation Stability, focuses on monoclonal antibody aggregation highlighting liquid formulation stability through the use of excipients and the importance of high quality chemicals.

References:

1. Wang W., et al. “Impact of residual impurities and contaminants on protein stability” J Pharm Sci 2014, 103 (5), 1315-30:

2. Weinbuch D., et al. “Nanoparticulate Impurities in Pharmaceutical-Grade Sugars and their Interference with Light Scattering-Based Analysis of Protein Formulations”, Pharm Res 2015, 32, 2419-2427:


Get Connected!

Join EMD Millipore on your favorite social media outlet for the latest updates, news, products, innovations, and contests!
Visit us at:

Join us on LinkedIn:
Join the community on twitter:

Do not forget to subscribe to have better access to our videos!

mAb Protein aggregation,mAb Protein aggregates,mAb Aggregate management,mAb Aggregate removal,mAb Aggregate formation,mAb Aggregate clearance,mAb Aggregate separation,Eliminate mAb aggregates,Eliminate mAb contamination,Remove mAb aggregates,Manage mAb aggregates,Antibody aggregation,Antibody aggregates,Monoclonal antibody aggregation,Monoclonal antibody purification,mAb Aggregation in downstream,mAb contaminant clearance,Large molecule aggregation,